1.Efifcacy observation of intravenous iron and oral iron on anemia patients with chronic hemodialysis and study on the difference of oxidative stress reaction
Jingfang ZHAO ; Yuefang WANG ; Mei CHENG
Chinese Journal of Biochemical Pharmaceutics 2014;(2):162-164
Objective To explore the safety and efifciency of oral iron therapy and intravenous iron therapy in anemia patients with maintenance hemodialysis,in order to gain experience for clinical treatment of this disease. Methods 88 cases collected in the ifrst people's hospital of Changshu city from July 2010 to March 2013 were divided into research group(n=44) and control group(n=44) by random number table. Control group was given oral iron therapy, and research group was t given intravenous iron. The differences of hemoglobin (Hb), reticulocyte, serum ferritin content, superoxide dismutase (SOD) and serum malondialdehyde (MDA) before and after treatment between two goups were recorded and compared. Results The differences of Hb, serum ferritin and reticulocyte numerical before treatment between two groups were not signiifcant, but signiifcant four weeks after treatment, with higher level in research group(P<0.05).The difference of oxidative stress status before treatment between two groups was not signiifcant, but after treatment, the MDA level in research group was higher than control group(P<0.05),while SOD level was lower than control group(P<0.05). Conclusion Compared with oral iron therapy, intravenous iron has better results in improving anemia, but easy to induce oxidative stress reaction.
2.Determination of the residual orgamic solvents in Nalmefene Hydrochloride by headspace GC
Chinese Journal of Biochemical Pharmaceutics 2014;(2):148-150
Objective To develop a headspace GC method for simultaneously determining the residual organic solvents Ethanol, Diethyl ether, Acetone, Dichloromethane, Ethyl acetate, and Tetrahydrofuran in Nalmefene Hydrochloride. Methods Samples dissolved in DMF and six organic residual organic solvents were separated on a DB 624 capillary column (30.0 m×0.32 mm,1.8μm) with a FID detector. The inlet temperature was 220℃and the FID detector temperature was 250℃. The column temperature rose by program:the initial temperature was 35℃, maintained for 8 min, raise to 180cwith a rate of 30℃/min, maintained for 5 min. The heated temperature of the headspace oven was 80℃, the heated time lasted 30 min, and the injection volume was 1.0 mL. Results Six residual orgamic solvents, including Ethanol, Diethyl ether, Acetone, Dichloromethane, Ethyl acetate, and Tetrahydrofuran in Nalmefene Hydrochloride were completely separated. It was appeared to present a good linearity within the experimental concentration. The limit of detection for Ethanol, Diethyl ether, Acetone, ichloromethane, Ethyl acetate, and Tetrahydrofuran were 0.25,0.076,0.15,0.55,0.26 and 0.30μg?mL-1.The method has a good average recovery. Conclusion The method is proved to be accurate and sensitive after validation. It is suitable to determine the residual orgamic solvents in Nalmefene Hydrochloride .
3.Study on expression,puriifcation and properties of recombinant human Chymotrypsin
Chinese Journal of Biochemical Pharmaceutics 2014;(2):144-147
Objective To study the prokaryotic expression, puriifcation and properties of recombinant human Chymotrypsin. Methods The protein was highly expressed in E.coliBL 21 (DE 3) as inclusion body. After refolding and activated with trypsin, the activated protein was obtained and purified with ion-exchange chromatography(CM-FF), some properties of the recombinant human chymotrypsin was investigated. Results The molecular weight of chymotrypsinogen was about 30 KD in SDS-PAGE, total activity recovery rate of CM-FF puriifcation was 93.7%. The recombinant chymotrypsin kept stable from pH 3 to pH 5, and owned good temperature stability. Km was 0.067 mmol/L with BTEE as a substrate. The UV maximum absorption wavelength was 281 nm.Conculsion The recombinant human enzyme was expressed successfully, and a feasible production method to get a high activity of the recombinant human chymotrypsin was established.
4.Clinical observation on biifco combined with triple therapy for eradication of Helicobacter pylori
Chinese Journal of Biochemical Pharmaceutics 2014;(2):137-138
Objective To investigate the clinical efifcacy of biifco combined with triple therapy for eradication of Helicobacter pylori. Methods 84 cases with Helicobacter pylori infection were selected as the observation objects, and were randomly divided into treatment group and control group, 42 cases in each group. Control group used standard triple (omeprazole, amoxicillin, clarithromycin) oral;treatment group took biifco on the basis of control group use. Hp eradication rate, gastrointestinal symptoms and the incidence of adverse reaction in two groups after treatment were compared. Results Hp eradication rate in treatment group was 92.9%, higher than 75.0%in control group, the difference was statistically signiifcant(P<0.05);the incidence of adverse reaction in treatment group was 2.4%, signiifcantly lower than 10.0%in control group, the difference was statistically signiifcant (P<0.05);the total symptom relief rate in treatment group was 90.5%, signiifcantly higher than 75.0%in control group, the difference was statistically signiifcant(P<0.05). Conclusion The eradication rate of biifco combined with triple therapy for Helicobacter pylori is high and signiifcant, which can effectively reduce adverse gastrointestinal reactions.
5.Efifcacy of lamivudine in chronic hepatitis B antiviral therapy
Chinese Journal of Biochemical Pharmaceutics 2014;(2):135-136
Objective To evaluate the clinical efifcacy of lamivudine in chronic hepatitis B antiviral therapy. Methods 78 cases with chronic hepatitis B patients from January 2012 to December 2012 collected in People's Hospital of Deqing County were observed and randomly divided into experimental group and control group, 39 cases in each group. Control group were treated with entecavir , and experimental group with lamivudine. The negative rate of hepatitis B virus, hepatitis B virus surface antigen (hepatitis B surface antigen, HBsAg) seroconversion rates and alanine aminotransferase (Alamine aminotransferase, ALT) recovery rate after 6 weeks, 12 weeks , 18 weeks , 24 weeks of the two groups were compared. Results The negative rate of hepatitis B virus, ALT recovery rates in control group after 6 weeks, 12 weeks , 18 weeks, 24 weeks treatment were better than experimental group , the differences were statistically signiifcant(P<0.05). There was no signiifcant differences in the rate of HBsAg seroconversion at week 6 weeks, 12 weeks, 18 weeks, 24 weeks between two groups. Conclusion Lamivudine antiviral ,has acceptable clinical efifcacy in treatment for chronic hepatitis B, and still has a certain gap with entecavir, but it has an appropriate price, which may be more suitable for patients in economic. So choose which medicine in clinical application should be in combination with the practical situation of patients.
6.Clinical efifcacy and immunomodulatory effect ofpaclitaxel plus cisplatin in treatment of patient with advanced ovarian cancer
Chinese Journal of Biochemical Pharmaceutics 2014;(2):120-122
Objective To investigatethe the clinical efifcacy and immunomodulatory effect of paclitaxel and cisplatin in treatment of advanced ovarian carcinoma by different administration ways. Methods 94 patients with advanced ovarian carcinoma were randomly divided into observation group and control group. Patients in observation group (47 cases) were treats with paclitaxel plus cisplation by intraperitoneal infusion chemotherapy, the other patients (47 cases) who are in control group were treats with paclitaxel plus cisplation by intravenous chemotherapy. Two groups used the same medicinal dose, and 3 weeks as a course. After two courses, therapeutic effect and drug toxicity side effects were evaluated by measuring positive rate changes of peripheral blood immune cells (CD 4+CD 25+cell), the CD 4+/CD 8+ratio changes, progression-free survival and 3-year survival rate. Results The efifcacy of patients in two groups were evaluated objectively. Observation group of RR and DC were respectively 78.7%and 91.5%, signiifcantly higher than that of control group. To the end of follow-up period, two groups of progression-free surial compared with a signiifcant difference. After two courses of chemotherapy, positive rate of immune cells (CD 4+CD 25+cell) declined had signiifcant difference compared with before treatment. After two courses of chemotherapy, two groups of CD 4+/CD 8+ratio were increased, compared with before treatment, which is a signiifcant difference. The main adverse reactions of the two groups were myelosuppression and neurotoxicity, but there were no termination of tolerance for adverse reactions. Conclusion The programs with paclitaxel plus cisplatin peritoneal perfusion chemotherapy for advanced ovarian cancer which is effective, small toxic and safe, is worthy of clinical application.
7.Effects of glutamine combined with early enteral nutrition on severe acute pancreatitis’ systemic inlfammation
Guoxiang YANG ; Wanli ZHANG ; Hansong DU ; Ronglin ZHAI ; Li QIU
Chinese Journal of Biochemical Pharmaceutics 2014;(2):115-117
Objective To study the glutamine combined with early enteral nutrition’s effects on severe acute pancreatitis’systemic inlfammation. Methods 150 Cases with severe acute pancreatitis were divided into total parenteral nutrtion group(TPN group), early enteral nutrition group(EEN group) and Glutamine and early enteral nutrition group(G+EEN group) according to their therapeutic methods. The curative effects, APACHEⅡscore and liver and kidney function were compared after treatment. Inlfammatory cytokines of hs-CRP, TNF-α, IL-1β, IL-6, IL-8 and IL-10 before and after treatment were detected and compared. Results The efifciency rate in G+EEN group was signiifcantly better than that in TPN and EEN group(P<0.05), with lower APACHEⅡscore and better liver and kidney function. The level of hs-CRP, TNF-α, IL-1β, II-6 and IL-8 after treatment in G+EEN group were signiifcantly lower than that in TPN and EEN group(P<0.05), except IL-10, which was signiifcantly higher than that in TPN and EEN group (P<0.05). Conclusion Glutamine combined with early enteral nutrition could signiifcantly ameliorate severe acute pancreatitis’systemic inlfammation, its curative effects is better than early enteral nutrition and total parenteral nutrition.
8.Clinical study of Salviae Miltiorrhizae and Ligustrazine Hydrochloride Injection aided identiifcation and treatment of ischemic stroke
Wenkai LIU ; Huiliang XIAO ; Xuzhou ZHOU
Chinese Journal of Biochemical Pharmaceutics 2014;(2):110-111
Objective To observe the effect of Salviae Miltiorrhizae and Ligustrazine Hydrochloride Injection in inauxiliary treatment of ischemic stroke and its clinical efficacy. Methods 142 cases of patients with ischemic stroke, were randomly divided into experimental group and control group. Control group(n=71) were treated with conventional therapy. Test group(n=71) were treated with Salviae Miltiorrhizae and Ligustrazine Hydrochloride Injection on the basis of conventional therapy. Hemorheological changes, nerve function improvement and treatment efifcacy in two groups before and after treatment were observed and analyzed. Results After treatment, the plasma viscosity and hematocrit in control group were 1.91±0.35, (49.58±1.04)%; while experimental group were 1.17±0.28, (38.97±1.31)%, the differences between two groups were signiifcant(P<0.05). Before treatment, the neurological function score in control group was 22.49±1.21, while experimental group was 23.18±1.74, there was no signiifcant difference between two groups. After treatment, the neurological function score in control group was 10.58±0.94, while experimental group was 4.62±2.05, the difference was signiifcant(P<0.05). The total effective rate was 80.3%in control group ,while 88.7% in experimental group, the difference was signiifcant(P<0.05). Conclusion The clinical efifcacy of Salviae Miltiorrhizae and Ligustrazine Hydrochloride Injection in auxiliary treatment of ischemic stroke was accurate, and it can alleviate the symptom of patients.
9.Clinical study of MRP and LRP mRNA expression in peple with human non-small cell lung cancer after cisplatin chemotherapy
Chinese Journal of Biochemical Pharmaceutics 2014;(2):108-109
Objective To investigate the mRNA expression of the multidrug resistance associated protein and lung resistance protein in human non-small cell lung cancer tissues and their relationship with cis-platinum. Methods 13 samples were collected from patients with non small cell lung cancer before and after chemotherapy, the mRNA expression of MRP and LRP were detected using RT-PCR method, correlation between two genes were studied by Logistic regression analysis. Results Compared with before cisplatin chemotherapy, MRP and LRP expression of patients were increased after chemotherapy(P<0.05).Logistic regression analysis showed that there is no correlation between the two genes(r=0.036,P<0.05). Conclusion Cisplatin chemotherapy can increase the mRNA expression of MRP and LRP, and there is no correlation between the two genes.
10.The clinical efifcacy of Matrine injection on malignant cancer pain treatment
Chinese Journal of Biochemical Pharmaceutics 2014;(2):104-105
Objective To evaluate the clinical efifcacy of Matrine injection on malignant cancer pain treatment. Methods 100 patients in Central Hospital of Huanggang from February 2010 to April 2013 were randomly divided into two groups(control group and research group) for retrospective study(n=50). Based on the conventional treatment, control group were received three-step analgesic ladder, and research group were treated with matrine injections. The pain scores and Karn of sky scores were evaluated and compared before and after treatment in each group, and were compared between two groups. Results The pain score and Karn of sky score in research group after treatment were signiifcantly better than control group(P<0.05). Conclusion Matrine injection could relief pain level and improve patients' quality of life of malignant cancer patient.